** MiRXES Holding 2629.HK climbs to HK$31.95 on HK debut, up 37.1% from offer price of HK$23.30
** Stock last up 31.8%, outpacing Hang Seng Index's .HSI 0.5% gain and Hang Seng Biotech index's .HSHKBIO 2.3% jump
** Singapore-headquartered micro ribonucleic acid (miRNA) tech co, which specialises in early cancer detection and precision medicine, sells 46.6 mln shares in global offering, raising HK$1.09 bln ($139.2 mln) for R&D, manufacturing, commercialisation of core product
** Jiangsu Hengrui Pharmaceuticals 1276.HK jumps to HK$60.5 on HK debut, up 37.3% from offer price of HK$44.05
** Chinese oncology drug developer sells 224.52 mln H-shares, raising HK$9.89 bln ($1.26 bln) for R&D, constructing production facilities
** Hengrui's Shanghai stock 600276.SS slips 1.6%
($1 = KH$7.8302)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.